Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist.
Saved in:
| Title: | Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist. |
|---|---|
| Authors: | Burstein ES; Acadia Pharmaceuticals Inc, San Diego, California. Electronic address: eburstein@acadia-pharm.com., Olsson R; Chemical Biology and Therapeutics, Department of Experimental Medical Science, Lund University, Lund, Sweden., Skold N; RG Discovery, Lund, Sweden., Jansen KE; RG Discovery, Lund, Sweden., Azar M; Behavioral Pharma, La Jolla, California., Sandiego C; Perceptive Discovery, New Haven, Connecticut., Ridler K; Perceptive Discovery, London, United Kingdom., Rabiner EA; Perceptive Discovery, London, United Kingdom., Rhodes G; GRhodes Pharma Consulting, Los Altos, California., Dey PM; Acadia Pharmaceuticals Inc, Princeton, New Jersey., Pathak S; Acadia Pharmaceuticals Inc, Princeton, New Jersey. |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2026 Jun; Vol. 393 (6), pp. 104932. Date of Electronic Publication: 2026 May 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1521-0103 |
|---|---|
| DOI: | 10.1016/j.jpet.2026.104932 |
